| COR |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$4.45 vs. cons $4.37 |
MEDIUM |
| COR |
Report |
U.S. Healthcare Solutions operating income |
BEAT |
pred ~$1.07B vs. cons $1.04B |
MEDIUM |
| COR |
Report |
Consolidated revenue |
IN-LINE |
pred ~$84.25B vs. cons $84.35B |
MEDIUM |
| COR |
Guide |
FY26 adjusted diluted EPS guidance |
BETTER |
guide ~$17.88 midpoint vs. cons $17.79 (FY26) |
MEDIUM |
| COR |
Guide |
FY26 consolidated revenue-growth guidance |
UNCHANGED |
guide ~5.0% midpoint vs. cons 5.0% (FY26) |
HIGH |
| COR |
Guide |
FY26 U.S. Healthcare Solutions operating-income-growth guidance |
UNCHANGED |
guide ~15.0% midpoint vs. cons 15.0% (FY26) |
MEDIUM |
| COR |
Guide |
FY26 adjusted free-cash-flow guidance |
UNCHANGED |
guide ~$3.00B vs. cons $3.00B (FY26) |
MEDIUM |
| COR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| COR |
Return |
5-day cumulative residual |
+1.0% (FADE) |
A modest EPS and U.S. operating-income beat, plus a small FY26 EPS-guide increase, should initially validate earnings quality. However, an unchanged 4%-6% revenue framework and only modest guide upside leave implied fiscal-Q4 EPS at roughly $4.55 versus ~$4.60 in prior consensus math, limiting out-period estimate revisions after the initial move. |
MEDIUM |